An observational study in Papillary Thyroid Cancer, sponsored by Istituto Auxologico Italiano. Recruiting at 1 site in Italy. Per ClinicalTrials.gov, last updated 2024-10-08.
Sponsored by Istituto Auxologico Italiano · Observational
Somatic mutations in the MAP (mitogen-activated protein) kinase pathway have been found in about 80% of papillary thyroid tumors (PTCs). The evaluation of the PTC mutational profile is crucial for the definition of the prognosis and for predicting the effects of targeted and personalized therapies. Molecular characterization by mass spectrometry (Mass ARRAY) allows the search for multiple mutations in a single experiment, in a sensitive, fast and economic way. A Mass ARRAY platform (PTC-MA) was developed, capable of identifying the presence of the most common somatic point mutations and rearrangements in PTC (Pesenti et al., Endocrine 2017). The aim of the study is to characterize the mutational profile of a large series of papillary thyroid carcinomas (PTC). Tumor samples will be analyzed using our PTC-MA platform. The molecular profile of PTCs will be correlated with the clinical and prognostic characteristics of the patients.
178 studies on the registry are indexed under Thyroid Cancer, Papillary; 54 are open to participants now.
This study's planned enrollment of 600 is above the median of 200 across 67 observational studies indexed under Thyroid Cancer, Papillary.
Browse Thyroid Cancer, Papillary studies →Istituto Auxologico Italiano is the lead sponsor of 202 studies on the registry; 78 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients diagnosed with papillary thyroid cancer, operated and followed by our Center of Excellence for the Diagnosis and Treatment of Thyroid Tumors
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Genetic: Genotyping
Characterization of genetic profile of tumor tissues
Mutational profile of PTCs
The mutational profile of about 600 PTCs will be characterized and correlate with the clinical characteristics and patient outcomes
Time frame: years 1-8
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istituto Auxologico Italiano →